Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Cancer. 2019 Feb;108:100-110. doi: 10.1016/j.ejca.2018.12.005. Epub 2019 Jan 14.

Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.

Author information

1
Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Department of Biomedical, Experimental, and Clinical Sciences, University of Florence, Florence, Italy.
2
Cancer Risk Factors and Lifestyle Epidemiologyu Unit, Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy.
3
Onco-Hematology Unit, Policlinico San Marco-IOB, Zingonia, Bergamo, Italy.
4
UOSD Diabetologia Endocrinologia, Ospedale S. Giuseppe, Empoli, Italy.
5
Senology Radiology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
6
Breast Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
7
Pathology Division, Azienda Ospedaliero-Universitaria Careggi, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
8
Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Department of Biomedical, Experimental, and Clinical Sciences, University of Florence, Florence, Italy. Electronic address: icro.meattini@unifi.it.

Abstract

AIM:

We present the final results of the BONADIUV trial, a single-blind, randomised, placebo-controlled phase 2 study to evaluate the impact of ibandronate treatment on bone mineral density (BMD) in osteopenic women taking aromatase inhibitors (AI).

PATIENTS AND METHODS:

Between 2011 and 2014, 171 osteopenic patients were randomised in a 1:1 ratio to receive either placebo or oral monthly ibandronate (150 mg). Treatment duration was 2 years, with 6-month evaluation. Primary end-point was the 2-year lumbar spine (LS) and total hip (TH) T-score mean differences as measure of BMD variation. Secondary analyses of survival outcomes have been performed at a 5-year median follow-up. CLINICALTRIALS.

GOV IDENTIFIER:

NCT02616744.

RESULTS:

Median age of study population was 60.2 years (range 44-75). At the database cut-off time, the median follow-up was 63.3 months (range 2.7-87.3). No difference in terms of T-score was shown at baseline between arms both for TH (P = 0.61) and LS (P = 0.96). At 2-year follow up, the mean change was statistically significant in favour of ibandronate arm both at TH (P = 0.0002) and LS (P < 0.0001). No significant difference in terms of adverse events was observed between arms. At a median follow-up of 63.3 months (range 2.7-87.3), the overall survival (OS) rate was 97.5% in the placebo group and 93.0% in the ibandronate arm (P = 0.19). The invasive disease-free survival (iDFS) rates did not differ between groups (P = 0.42).

CONCLUSIONS:

Ibandronate compared to placebo improved BMD change in osteopenic women treated with adjuvant AI. Five-year survival analyses showed no difference between arms in terms of OS and iDFS rates.

KEYWORDS:

Bisphosphonates; Bone loss; Breast cancer; Endocrine therapy; Ibandronate; Phase 2; Randomised trial; Survival

PMID:
30648627
DOI:
10.1016/j.ejca.2018.12.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center